Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events
Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups
Benefits of blarcamesine on both amyloid-beta and brain volume, two underlying pathological hallmarks of Alzheimer’s disease
EMA submission expected in Q4
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.